NEW YORK, NY--(Marketwired - May 05, 2014) - Nuvilex, Inc. (OTCQB: NVLX) continued to awe investors last week with yet another marquee name that has agreed to work with its pancreatic cancer treatment of Cell-in-a-Box® combined with the anticancer drug ifosfamide. As the company heads into late phase clinical trials, it will do so with both a familiar name to the treatment and to the field of oncology in Dr. Matthias Lohr of the famed Karolinska Institute in Stockholm, Sweden.
Outside of Austrianova's Dr.'s Gunzburg and Salmons, there may not be a bigger fan of this advanced pancreatic cancer treatment than Dr. Lohr. After all, Dr. Lohr along with Dr.'s Gunzburg and Salmons collaborated to write and publish an Abstract where they called the treatment using encapsulated live-cells capable of activating the anticancer drug ifosfamide into its cancer killing form at the site of the tumor: "The Magic Bullets of the 21st Century."
Today, we know that treatment as the Cell-in-a-Box® technology combined with ifosfamide that Nuvilex will use to go head to head with the "gold standard" for pancreatic cancer, Celegene's Abraxane® plus gemcitabine.
While Nuvilex is a small international biotech firm, it is attracting some of the biggest names in oncology, and some of the greatest minds in pancreatic cancer. With Dr. Lohr agreeing to continue his work with what is now Nuvilex's treatment, it marks what should be seen as another strong endorsement that there is something attractive about what the Cell-in-a-Box®/ifosfamide combination can contribute to advanced pancreatic cancer.
Clearly the sharpest minds in the industry think Nuvilex's treatment can move the needle on this deadly cancer, and having Dr. Lohr, who was the Principal Investigator in the treatment's two successful Phase 1/2 clinical trials, back "in the fold" is truly a great "get" for Nuvilex and its executives.
About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with Reports, Interviews and Articles. SMMG is compensated for Nuvilex articles, reports, and interviews by a third party who reserves the right to buy, sell or remain neutral on securities after the publication of this article. SMMG has received total compensation of $81,695 for content related to Nuvilex. Additionally, a principal at SMMG currently owns 200,000 total shares of Nuvilex issued by the company through a consulting agreement which has since ended for work unrelated to content development. The shares have been held for the requisite period under Rule 144 as of April 30, 2013, and are eligible to be sold immediately. None of the Rule 144 eligible shares have been sold; however, the principal reserves the right to sell all or part of those shares in Nuvilex at any time without further notice. For more information: www.stockmarketmediagroup.com.